Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
13453 | 772 | 39.2 | 92% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
630 | 13104 | CYTOMEGALOVIRUS//HUMAN CYTOMEGALOVIRUS//HHV 6 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CMV SPECIFIC T CELLS | Author keyword | 12 | 86% | 1% | 6 |
2 | ONCOHEMATOL GRP | Address | 9 | 83% | 1% | 5 |
3 | CYTOMEGALOVIRUS SPECIFIC T CELLS | Author keyword | 8 | 100% | 1% | 5 |
4 | CYTOKINE FLOW CYTOMETRY | Author keyword | 6 | 50% | 1% | 8 |
5 | S CORE UNIT | Address | 6 | 100% | 1% | 4 |
6 | CMV PP65 | Author keyword | 5 | 60% | 1% | 6 |
7 | IMMUNOCYTOMETRY SYST | Address | 5 | 63% | 1% | 5 |
8 | PROTEIN SPANNING PEPTIDE POOLS | Author keyword | 4 | 75% | 0% | 3 |
9 | STREPTAMERS | Author keyword | 4 | 75% | 0% | 3 |
10 | PP65 | Author keyword | 4 | 31% | 1% | 11 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CMV SPECIFIC T CELLS | 12 | 86% | 1% | 6 | Search CMV+SPECIFIC+T+CELLS | Search CMV+SPECIFIC+T+CELLS |
2 | CYTOMEGALOVIRUS SPECIFIC T CELLS | 8 | 100% | 1% | 5 | Search CYTOMEGALOVIRUS+SPECIFIC+T+CELLS | Search CYTOMEGALOVIRUS+SPECIFIC+T+CELLS |
3 | CYTOKINE FLOW CYTOMETRY | 6 | 50% | 1% | 8 | Search CYTOKINE+FLOW+CYTOMETRY | Search CYTOKINE+FLOW+CYTOMETRY |
4 | CMV PP65 | 5 | 60% | 1% | 6 | Search CMV+PP65 | Search CMV+PP65 |
5 | PROTEIN SPANNING PEPTIDE POOLS | 4 | 75% | 0% | 3 | Search PROTEIN+SPANNING+PEPTIDE+POOLS | Search PROTEIN+SPANNING+PEPTIDE+POOLS |
6 | STREPTAMERS | 4 | 75% | 0% | 3 | Search STREPTAMERS | Search STREPTAMERS |
7 | PP65 | 4 | 31% | 1% | 11 | Search PP65 | Search PP65 |
8 | CMV REACTIVATION | 3 | 35% | 1% | 6 | Search CMV+REACTIVATION | Search CMV+REACTIVATION |
9 | CYTOKINE SECRETION ASSAY | 2 | 44% | 1% | 4 | Search CYTOKINE+SECRETION+ASSAY | Search CYTOKINE+SECRETION+ASSAY |
10 | ANTIGEN SPECIFIC T CELLS | 2 | 18% | 1% | 11 | Search ANTIGEN+SPECIFIC+T+CELLS | Search ANTIGEN+SPECIFIC+T+CELLS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PROTEIN PP65 | 61 | 60% | 9% | 67 |
2 | PROPHYLACTIC INFUSION | 38 | 84% | 3% | 21 |
3 | LYMPHOCYTE CTL RESPONSE | 27 | 72% | 3% | 21 |
4 | ALLOGENEIC BONE MARROW | 26 | 25% | 12% | 91 |
5 | HLA PEPTIDE TETRAMERS | 12 | 75% | 1% | 9 |
6 | CYTOMEGALOVIRUS SPECIFIC CD4 | 11 | 44% | 2% | 19 |
7 | PP65 | 10 | 34% | 3% | 25 |
8 | CMV INFECTION | 10 | 13% | 9% | 73 |
9 | MATRIX PROTEIN PP65 | 9 | 64% | 1% | 9 |
10 | HUMAN CYTOMEGALOVIRUS PP65 | 9 | 83% | 1% | 5 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care | 2014 | 7 | 53 | 55% |
Controlling Cytomegalovirus: Helping the Immune System Take the Lead | 2014 | 6 | 92 | 28% |
The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation | 2012 | 8 | 49 | 51% |
Multimer monitoring of CMV-specific T cells in research and in clinical applications | 2014 | 1 | 86 | 59% |
Dynamics of T cell memory in human cytomegalovirus infection | 2008 | 40 | 131 | 31% |
Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients | 2012 | 10 | 40 | 40% |
Adoptive T cell immunotherapy for cytomegalovirus | 2009 | 14 | 55 | 56% |
Adoptive immunotherapy of HCMV infection | 2007 | 13 | 78 | 60% |
Human cytomegalovirus vaccine: time to look for alternative options | 2006 | 44 | 66 | 41% |
Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry | 2013 | 7 | 100 | 43% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ONCOHEMATOL GRP | 9 | 83% | 0.6% | 5 |
2 | S CORE UNIT | 6 | 100% | 0.5% | 4 |
3 | IMMUNOCYTOMETRY SYST | 5 | 63% | 0.6% | 5 |
4 | VIRAL IMMUNOL UNIT | 3 | 57% | 0.5% | 4 |
5 | PROGRAM CELL ENHANCEMENT TECHNOL IMMUNOTHER Y | 3 | 45% | 0.6% | 5 |
6 | BLOOD MARROW TRANSPLANT SERV | 3 | 24% | 1.3% | 10 |
7 | SYDNEY CELLULAR THER IES | 2 | 38% | 0.6% | 5 |
8 | HEMATOL CELL TRANSPLANTAT | 2 | 67% | 0.3% | 2 |
9 | MARROW TRANSPLANTAT PROGRAM | 2 | 67% | 0.3% | 2 |
10 | MED KLIN WERPUNKT NEPHROL INTERNIST INTENSIV | 2 | 67% | 0.3% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000196156 | CYTOMEGALOVIRUS//VALGANCICLOVIR//GANCICLOVIR |
2 | 0.0000185022 | MURINE CYTOMEGALOVIRUS//MCMV//LY49H |
3 | 0.0000172448 | AUSTRALIAN VACCINE DEV TUMOUR IMMUNOL//EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1//JOINT ONCOL PROGRAM |
4 | 0.0000124977 | HUMAN CYTOMEGALOVIRUS//HCMV//US28 |
5 | 0.0000117671 | CHIMERIC ANTIGEN RECEPTOR//ADOPTIVE CELL THERAPY//CHIMERIC IMMUNE RECEPTOR |
6 | 0.0000107442 | CD4CD28 T CELLS//CD4CD28NULL T CELLS//CD4CD28NULL CELLS |
7 | 0.0000088125 | CAROLINA CANC NANOTECHNOL EXCELLENCE//ARTIFICIAL ANTIGEN PRESENTING CELL//SLOAN KETTERING CANC |
8 | 0.0000084092 | IG LEVELS//LEUKEMIC CHILDREN//PROGNOSIS SURVIVAL |
9 | 0.0000081424 | PARTNERS AIDS//HIV PATHOGENESIS PROGRAMME//DORIS DUKE MED |
10 | 0.0000080409 | INTERDISCIPLINARY PROGRAM IMMUNOL//INTEGRATED IMMUNOL VACCINE//T CELL COMPETITION |